LSQ-28

LSQ-28: sourced facts only. name: "Herein, we developed LSQ-28 as a novel HDAC3 inhibitor, which exhibited high HDAC3 inhibitory activity (IC50 = 42 nM, SI > 161) and displayed potent antiproliferative activity against four cancer cells and further demonstrated excellent antimigratory, anti-invasive, and antiwound healing activities." [PMID:39873221]; target: "Herein, we developed LSQ-28 as a novel HDAC3 inhibitor, which exhibited high HDAC3 inhibitory activity (IC50 = 42 nM, SI > 161) and displayed potent antiproliferative activity against four cancer cells and further demonstrated excellent antimigratory, anti-invasive, and antiwound healing activities." [PMID:39873221]; developer: "Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Disease, Ministry of Education; Jiangxi Provincal Key Laboratory of Tissue Engineering; College of Pharmacy, Gannan Medical University, Ganzhou 314000, China." [PMID:39873221]; stage: "When combined with olaparib, LSQ-28 significantly enhanced the in vivo tumor-suppression activity (TGI = 91%)." [PMID:39873221]